Patient-centered home care for Black men with advanced prostate cancer
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Advanced Prostate Cancer (CaP)
This study is trying out a home care approach for Black men with advanced prostate cancer to see if it can improve their quality of life and meet their treatment preferences.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 77 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | denosumab, chemotherapy |
| Locations | 1 site (Jacksonville, Florida) |
| Trial ID | NCT06470750 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the feasibility of a patient-centered home care model aimed at reducing health disparities and improving quality of life for Black men with advanced prostate cancer. Participants will be divided into two groups: one will engage in focus groups and interviews, while the other will complete questionnaires throughout the study. The study aims to assess patient preferences regarding treatment locations and the impact of home care on patient-reported outcomes and health-related quality of life.
Who should consider this trial
Good fit: Ideal candidates are Black men aged 18 and older with histologically confirmed prostate adenocarcinoma who are currently requiring therapy.
Not a fit: Patients who do not identify as Black or who do not have advanced prostate cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life and treatment experiences for Black men facing advanced prostate cancer.
How similar studies have performed: While this approach is innovative, similar studies focusing on patient-centered care have shown promise in improving outcomes in various populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * GROUP 1 FOCUS GROUPS: * Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer * GROUP 1 SURVEYS: * Are 18 years of age or older * Have histologic evidence of prostate adenocarcinoma * Are requiring, have required, or will require prostate cancer treatment * Have an understanding of the protocol and its requirements * Are willing to fill in a questionnaire and participate in a focused interview * Are able and willing to sign an informed consent * GROUP 1 INTERVIEWS: * Enrollment in the survey phase of the protocol * GROUP 2: * Are 18 years of age or older * Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges) * Have histologic evidence of prostate adenocarcinoma * Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel) * Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW) * Have an understanding of the protocol and its requirements * Are able and willing to sign informed consent Exclusion Criteria: * GROUP 1 FOCUS GROUPS: * Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system * GROUP 1 SURVEYS: * Do not identify as Black men * Have not been diagnosed with prostate cancer * GROUP 1 INTERVIEWS: * Not enrolled in the survey phase of the protocol * GROUP 2: * Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges) * Have not been diagnosed with histologic evidence of prostate adenocarcinoma * Are not requiring active standard anti-cancer therapy
Where this trial is running
Jacksonville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Roxana S. Dronca, MD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.